A Novel BRCA1 Pathogenic Variant in Tunisian Patient With High Grade Ovarian Cancer: Favorable Therapeutic Response to Olaparib.
Nihel Ammous-Boukhris, Rania Abdelmaksoud-Dammak, Ameni Feki et al.
✦ AI-curated · Sources linked
Case in brief
A 50-year-old woman presented with severe anemia due to heavy menometrorrhagia. Initial evaluations were unremarkable, but exploratory laparotomy revealed a peritoneal nodule. Genetic testing identified a novel pathogenic BRCA1 variant. Following first-line chemotherapy, the patient was treated with olaparib, resulting in a progression-free survival of 23 months without disease recurrence.
What made this case unusual
The case features a novel BRCA1 pathogenic variant identified only in tumor tissues, expanding the known mutational spectrum in high-grade serous ovarian cancer.
Diagnostic / clinical pearl
Clinicians should consider integrating tumor-based genomic profiling with germline testing to identify actionable mutations in ovarian cancer.
Why it matters
This case emphasizes the need for including underrepresented populations in genomic studies to enhance understanding of cancer genetics.